[Frontiers in Bioscience E3, 125-136, January 1, 2011]

BRCA1-related gene signature in breast cancer: the role of ER status and molecular type

Katarzyna Marta Lisowska1, Volha Dudaladava1,2, Michal Jarzab1, Tomasz Huzarski3, Ewa Chmielik4, Ewa Stobiecka4, Jan Lubinski3, Barbara Jarzab5

1Department of Tumor Biology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, 2currently: Department of Medical Biology and Genetics, Grodno State Medical University, Grodno, Belarus, 3International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland, 4Department of Pathology Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland, 5Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

FIGURES

Figure 1. Principal Component Analysis reveals that major sources of variability in gene expression are related to the molecular subtype of tumor and estrogen receptor activity. Thirty five breast cancer samples were analyzed. First two principal components are shown. The distance between the samples reflects differences in gene expression profile. A. Tumor samples are colored according to hereditary versus sporadic status and BRCA genes truncation: BRCA1-mutated tumors - red, BRCA1-methylated tumors - pink, BRCA2-mutated - purple, BRCAx - blue, FCA - light blue, sporadic breast cancer - green. B. Samples are colored according to the estrogen receptor expression level, as measured by microarrays: red - highest expression, green - lowest expression. C. Samples are colored according to the molecular subtype: cyan - basal-like molecular subtype magenta - luminal-like molecular subtype (as defined by Sorlie et al. (7)). D. Samples are colored according to the histopatological type: medullary breast ca. - blue, ductal breast ca. - green